Mentioned as a liked small-cap biotech name that could be an M&A target, potentially leading to sharp stock price increases.

A contrarian bullish opportunity; the market may be overly skeptical of the Chinese data for its drug Ivonescamab. It is a high-risk, high-reward play that could be significantly undervalued if the drug is successful.

Considered a very compelling bullish signal due to two co-CEOs each purchasing $6 million in stock after a recent price drop, with one insider having a strong track record.